PRE-ANNOUNCEMENT: the information below is indicative and subject to change until the official call is published

ERA4Health is expected to launch the NanoDiagNCD transnational call to support translational research projects developing nanotechnology-based diagnostic and theranostic tools for non-communicable diseases.

According to the pre-announcement, projects are expected to:

• Develop and/or validate diagnostic and theranostic tools based on robust scientific evidence.
• Improve prevention, early disease detection, disease monitoring, treatment guidance, and risk/benefit assessment across the care continuum.
• Demonstrate added value versus existing diagnostic approaches through validated performance benchmarks.
• Address translational and adoption aspects such as scalability, manufacturability, standardisation, affordability, accessibility, cost-effectiveness, regulatory readiness, interoperability, and healthcare system integration.
• Have a project duration of 36 months.

Objective: To advance nano-enabled diagnostic and theranostic solutions that improve the detection and clinical management of non-communicable diseases.

Only transnational projects are eligible.

• Applicants may belong to:
  • Academia
  • Clinical/public health sector
  • Enterprises
  • Operational stakeholders
• Each application must include partners applying for funding from at least two of the three categories: Academia (A), Clinical/public health sector (B), and Enterprises (C).
• Consortium must include a minimum of 3 and a maximum of 5 eligible partners from at least 3 different participating countries.
• At least 2 eligible partners must come from different EU Member States or Horizon Europe Associated Countries participating in the call.
• The maximum number of eligible partners may increase to 6 or 7 if one or two eligible partners respectively are included from Lithuania, Slovakia, or Taiwan.
• No more than 2 eligible partners from the same country.
• Maximum of 2 collaborators as self-funded partners not applying for funding.
• Participating countries/funding organisations include: Belgium, Egypt, France, Greece (pending confirmation), Hungary, Israel, Italy, Latvia, Lithuania, Norway, Netherlands, Poland, Portugal (pending confirmation), Romania, Slovakia, Spain, Taiwan and Türkiye.
• Proposals where nanotechnology is not central are not eligible.
• Discovery of new biomarkers is excluded. Development and technological improvement of known biomarkers is allowed.
• Infectious diseases are excluded, although chronic diseases resulting from past infectious diseases are allowed.
• Eligibility of individual partners may vary according to national/regional regulations.

In case of interest, please click on 'm'interessa' and we will contact you.